A case of cellular alchemy: lineage reprogramming and its potential in regenerative medicine.

A case of cellular alchemy: lineage reprogramming and its potential in regenerative medicine.
复制标题

DOI:
10.1093/jmcb/mjs005
复制
发表时间:
2012-08
影响因子:
5.5
通讯作者:
G. Asuelime;Yanhong Shi
G. Asuelime;Yanhong Shi
中科院分区:
生物学1区
文献类型:
--
作者:
G. Asuelime;Yanhong Shi

文献摘要

被引文献

相似文献

随着越来越多的关于细胞命运重编程中观察到的诱导转化的报告出现,再生医学领域正在迅速获得动力。虽然近年来,许多注意力集中在将命运定型的体细胞转化为胚胎样或多能状态,但仍存在与诱导多能干细胞重编程的应用相关的许多限制,包括相对低的重编程效率、重编程事件发生所需的时间、表观遗传不稳定性以及与多能状态相关的致瘤性。另一方面,谱系重编程涉及从一种成熟细胞类型转化为另一种成熟细胞类型,而不经历转化为不稳定的中间体。它为再生医学提供了一种替代方法,具有相对较低的肿瘤发生风险,并在特定细胞环境中提高了效率。虽然谱系重编程提供了令人兴奋的潜力,但在这项技术准备好应用于临床之前,仍有许多工作要做。
The field of regenerative medicine is rapidly gaining momentum as an increasing number of reports emerge concerning the induced conversions observed in cellular fate reprogramming. While in recent years, much attention has been focused on the conversion of fate-committed somatic cells to an embryonic-like or pluripotent state, there are still many limitations associated with the applications of induced pluripotent stem cell reprogramming, including relatively low reprogramming efficiency, the times required for the reprogramming event to take place, the epigenetic instability, and the tumorigenicity associated with the pluripotent state. On the other hand, lineage reprogramming involves the conversion from one mature cell type to another without undergoing conversion to an unstable intermediate. It provides an alternative approach in regenerative medicine that has a relatively lower risk of tumorigenesis and increased efficiency within specific cellular contexts. While lineage reprogramming provides exciting potential, there is still much to be assessed before this technology is ready to be applied in a clinical setting.